Registration Study of Glembatumumab vedotin (CDX-011) in Patients with Triple Negative Breast Cancer Over-expressing GPNMB (Currently Enrolling)

Currently Enrolling


This two arm, randomized trial is evaluating the efficacy and safety of Glembatumumab vedotin in patients with metastatic triple negative breast cancer with GPNMB over-expression who have progressed after receiving anthracyclines and taxanes, two agents normally used to treat metastatic breast cancer. Eligible patients are being randomized to either Glembatumumab vedotin or capecitabine, also known by the trade name Xeloda®, a treatment currently approved by the Food and Drug Administration for the treatment for metastatic breast cancer in a 2:1 fashion. Patients are being treated until disease progression or unacceptable toxicity and all patients will be followed for survival. This trial initiated in December 2013.

Xeloda® is a registered trademark of Genentech, a member of the Roche group.